Jan Anderl

1.0k total citations
18 papers, 801 citations indexed

About

Jan Anderl is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Jan Anderl has authored 18 papers receiving a total of 801 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Molecular Biology. Recurrent topics in Jan Anderl's work include Monoclonal and Polyclonal Antibodies Research (9 papers), HER2/EGFR in Cancer Research (8 papers) and Glycosylation and Glycoproteins Research (3 papers). Jan Anderl is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), HER2/EGFR in Cancer Research (8 papers) and Glycosylation and Glycoproteins Research (3 papers). Jan Anderl collaborates with scholars based in Germany, United States and China. Jan Anderl's co-authors include Heinz Faulstich, Ingrid Herr, Alexei V. Salnikov, Gerhard Moldenhauer, Christian Lutz, M. Hoberg, Tobias V. Lanz, Michael Weller, Wolfgang Wick and Isabel Tritschler and has published in prestigious journals such as Nature, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Jan Anderl

18 papers receiving 774 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Anderl Germany 10 351 307 209 194 160 18 801
Eva Løbner Lund Denmark 15 408 1.2× 235 0.8× 86 0.4× 62 0.3× 72 0.5× 45 753
Eckart Richter Germany 9 371 1.1× 184 0.6× 272 1.3× 175 0.9× 56 0.3× 15 972
Momoe Itsumi Japan 17 455 1.3× 182 0.6× 134 0.6× 25 0.1× 251 1.6× 38 1.0k
Katie L. Owen Australia 7 224 0.6× 312 1.0× 44 0.2× 52 0.3× 203 1.3× 9 640
Yingzi Ge Germany 16 419 1.2× 600 2.0× 150 0.7× 29 0.1× 665 4.2× 22 1.2k
Tao Ma China 11 434 1.2× 206 0.7× 96 0.5× 28 0.1× 85 0.5× 46 787
Ismaël Hervé Koumakpayi Canada 15 801 2.3× 301 1.0× 37 0.2× 76 0.4× 102 0.6× 24 1.2k
Evelyn Aranda United States 11 412 1.2× 210 0.7× 29 0.1× 49 0.3× 106 0.7× 12 753
Kenneth E. Hook United States 9 415 1.2× 338 1.1× 47 0.2× 107 0.6× 32 0.2× 15 785
Reginald Brys Belgium 13 343 1.0× 205 0.7× 101 0.5× 20 0.1× 176 1.1× 31 841

Countries citing papers authored by Jan Anderl

Since Specialization
Citations

This map shows the geographic impact of Jan Anderl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Anderl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Anderl more than expected).

Fields of papers citing papers by Jan Anderl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Anderl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Anderl. The network helps show where Jan Anderl may publish in the future.

Co-authorship network of co-authors of Jan Anderl

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Anderl. A scholar is included among the top collaborators of Jan Anderl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Anderl. Jan Anderl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Dickgießer, Stephan, Nicolas Rasche, Min Shan, et al.. (2025). Elucidating Critical Factors of Internalization and Drug Release of Antibody-Drug Conjugates (ADCs) Using Kinetic Parameters Evaluated by a Novel Tool Named TORCH. Bioconjugate Chemistry. 36(5). 945–959. 1 indexed citations
2.
Amendt, Christiane, et al.. (2024). Abstract ND08: M3554, a novel anti-GD2 antibody drug conjugate. Cancer Research. 84(7_Supplement). ND08–ND08. 5 indexed citations
3.
Tonillo, Jason, Dániel Schwarz, Christian Schröter, et al.. (2024). Welding PROxAb Shuttles: A Modular Approach for Generating Bispecific Antibodies via Site-Specific Protein–Protein Conjugation. Bioconjugate Chemistry. 35(6). 780–789. 3 indexed citations
4.
5.
Jäger, Sebastian, Doreen Könning, Nicolas Rasche, et al.. (2023). Generation and Characterization of Iduronidase-Cleavable ADCs. Bioconjugate Chemistry. 34(12). 2221–2233. 9 indexed citations
6.
Uhl, Philipp, et al.. (2022). Antibody–drug conjugates: What drives their progress?. Drug Discovery Today. 27(10). 103311–103311. 16 indexed citations
7.
Liu, Yunhua, Xinna Zhang, Cecil Han, et al.. (2021). Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 597(7875). E6–E6. 3 indexed citations
8.
Dickgießer, Stephan, Nicolas Rasche, Federico Riccardi Sirtori, et al.. (2021). Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates. Journal of Pharmaceutical Sciences. 110(12). 3776–3785. 24 indexed citations
9.
Dickgießer, Stephan, Christian Schröter, Jason Tonillo, et al.. (2020). Site-Specific Conjugation of Native Antibodies Using Engineered Microbial Transglutaminases. Bioconjugate Chemistry. 31(4). 1070–1076. 42 indexed citations
10.
Liu, Yunhua, Xinna Zhang, Cecil Han, et al.. (2015). TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 520(7549). 697–701. 168 indexed citations
11.
Hechler, Torsten, Christoph Müller, Andreas Pahl, & Jan Anderl. (2015). Abstract 633: Amanitin-based ADCs with an improved therapeutic index. Cancer Research. 75(15_Supplement). 633–633. 1 indexed citations
12.
Lutz, Christian, et al.. (2014). A novel, non-radioactive eukaryotic in vitro transcription assay for sensitive quantification of RNA polymerase II activity. BMC Molecular Biology. 15(1). 7–7. 7 indexed citations
13.
Hechler, Torsten, Michael Kulke, Christoph Mueller, Andreas Pahl, & Jan Anderl. (2014). Abstract 664: Amanitin-based antibody-drug conjugates targeting the prostate-specific membrane antigen. Cancer Research. 74(19_Supplement). 664–664. 11 indexed citations
14.
Anderl, Jan, Heinz Faulstich, Torsten Hechler, & Michael Kulke. (2013). Antibody–Drug Conjugate Payloads. Methods in molecular biology. 1045. 51–70. 58 indexed citations
15.
Moldenhauer, Gerhard, et al.. (2012). Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma. JNCI Journal of the National Cancer Institute. 104(8). 622–634. 154 indexed citations
16.
Anderl, Jan, Hartmut Echner, & Heinz Faulstich. (2012). Chemical modification allows phallotoxins and amatoxins to be used as tools in cell biology. Beilstein Journal of Organic Chemistry. 8. 2072–2084. 31 indexed citations
17.
Anderl, Jan, et al.. (2011). Abstract 3616: Highly potent antibody-amanitin conjugates cause tumor-selective apoptosis. Cancer Research. 71(8_Supplement). 3616–3616. 6 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eva Løbner Lund Breakdown of academic impact, for papers by Eckart Richter Breakdown of academic impact, for papers by Momoe Itsumi Breakdown of academic impact, for papers by Katie L. Owen Breakdown of academic impact, for papers by Yingzi Ge Breakdown of academic impact, for papers by Tao Ma Breakdown of academic impact, for papers by Ismaël Hervé Koumakpayi Breakdown of academic impact, for papers by Evelyn Aranda Breakdown of academic impact, for papers by Kenneth E. Hook Breakdown of academic impact, for papers by Reginald Brys
Rankless by CCL
2026